Nursing care
Hormone Replacement Therapy: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Hormone replacement therapy is prescribed at the lowest effective dose for the shortest duration needed to manage menopausal symptoms. Oestrogen-only therapy is used only after hysterectomy, since unopposed oestrogen raises endometrial cancer risk in a patient with an intact uterus, and every patient starting HRT needs an informed-consent conversation about clot and breast cancer risk.
Mechanism, simply
HRT replaces the oestrogen, and in most patients also the progestogen, that the ovaries stop producing at menopause. Oestrogen relieves vasomotor symptoms like hot flushes and night sweats, and helps preserve bone density. Progestogen is added to protect the endometrium from the proliferative effect of oestrogen alone.
In a patient who has had a hysterectomy, there's no endometrium to protect, so oestrogen-only therapy is appropriate and progestogen isn't needed. That single anatomical fact drives the whole prescribing decision, and it's the kind of detail the exam likes to test with a case stem rather than a direct question.
Indications you will see on the ward
Moderate to severe vasomotor symptoms are the leading indication, along with genitourinary syndrome of menopause, where vaginal oestrogen is often used locally rather than systemically. HRT is also used for prevention of osteoporosis in select patients, though it's rarely first-line for that purpose alone given the risk profile.
Premature ovarian insufficiency is a distinct indication, where HRT is given to a younger patient to replace hormones the body should still be producing, and the risk-benefit calculation there differs from HRT given at typical menopausal age.
Assessment before administration
Baseline history should cover personal or family history of breast cancer, venous thromboembolism, stroke, and liver disease, since these shift the risk-benefit balance or rule HRT out entirely. Blood pressure is checked at baseline and periodically thereafter.
Ask specifically whether the uterus is intact. This single question determines whether oestrogen-only or combined therapy is appropriate, and missing it is a scored error on medication safety questions.
Toxicity and the antidote
There's no antidote for oestrogen or progestogen overdose; management is supportive and the drug is discontinued if symptoms of overexposure occur, such as breast tenderness, nausea, or breakthrough bleeding. The bigger safety concern isn't acute toxicity but cumulative risk with duration of use.
This is why the lowest dose for the shortest time is the guiding principle rather than a slogan. Risk of breast cancer and venous thromboembolism rises with longer duration of combined HRT use, so therapy is reviewed regularly rather than continued indefinitely by default.
Interactions that matter
Enzyme-inducing anticonvulsants and rifampin can reduce HRT effectiveness by speeding hepatic metabolism, similar to their effect on oral contraceptives. St John's wort has the same enzyme-inducing effect and patients often don't think to mention an herbal supplement during a medication history.
Anticoagulant therapy needs closer monitoring when combined with HRT, since oestrogen itself has a procoagulant effect and can alter the balance a patient's anticoagulant dose was set around.
What the patient must be told
The informed-consent conversation has to include that combined HRT modestly increases the risk of breast cancer and venous thromboembolism, and that this risk rises with duration of use. Patients weighing symptom relief against these risks need the numbers presented as absolute risk, not just relative risk, because relative risk figures alone can sound more alarming than the actual change in likelihood.
Patients should also be told to report unusual vaginal bleeding, leg swelling or pain, chest pain, or sudden severe headache, which mirrors the ACHES pattern taught for oral contraceptives. Regular review, generally annual, is part of the plan from the start, not an afterthought.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why can't a patient with an intact uterus take oestrogen-only HRT?
Unpopposed oestrogen stimulates endometrial growth without the counterbalance progestogen provides, which raises the risk of endometrial hyperplasia and cancer. Oestrogen-only therapy is reserved for patients who have had a hysterectomy.
How long should a patient stay on HRT?
There's no fixed duration; it's individualised and reviewed regularly, guided by the principle of the lowest effective dose for the shortest time needed to manage symptoms. Many patients use it for a few years around the menopausal transition, though some continue longer under ongoing risk-benefit review with their prescriber.
Does HRT cause blood clots in every patient who takes it?
No, but it does raise the baseline risk of venous thromboembolism, particularly with oral combined formulations, and that risk is higher in patients who smoke, are obese, or have a personal or family clotting history. Transdermal oestrogen appears to carry a lower clot risk than oral formulations in current evidence, though practice on this varies by prescriber.
What should a nurse do if a patient on HRT reports sudden leg swelling?
Treat it as a possible deep vein thrombosis and escalate for prompt medical assessment rather than waiting for the next scheduled review. This is the same ACHES-pattern reasoning used for oral contraceptives, since both therapies carry procoagulant risk from oestrogen.
More on pharmacology
Guides on this